BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34645732)

  • 1. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
    Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
    Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
    Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
    Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
    Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
    Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants.
    Kaneda K; Yamashita Y; Morimoto T; Chatani R; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Takada T; Otsui K; Kimura T;
    Eur J Intern Med; 2023 Dec; 118():59-72. PubMed ID: 37574348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Safety and Effectiveness of Direct Oral Anticoagulants and Warfarin during Chemotherapy in Cancer Patients with Venous Thromboembolism Aged 75 Years or Older: A Nationwide Inpatient Database Study.
    Iwai C; Jo T; Konishi T; Kumazawa R; Matsui H; Fushimi K; Yasunaga H
    Gerontology; 2023; 69(5):561-570. PubMed ID: 36502790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants.
    Wee B; Lai J; Khattak Z; Kwok A; Donarelli C; Ho P; Lim HY; Lui B
    J Thromb Thrombolysis; 2024 Apr; 57(4):658-667. PubMed ID: 38393675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
    Campello E; Spiezia L; Simion C; Tormene D; Camporese G; Dalla Valle F; Poretto A; Bulato C; Gavasso S; Radu CM; Simioni P
    J Am Heart Assoc; 2020 Dec; 9(23):e018917. PubMed ID: 33222589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.